The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators
J Med Ethics
.
2022 Mar;48(3):193.
doi: 10.1136/medethics-2022-108157.
Epub 2022 Feb 3.
Authors
Erik Gustavsson
1
2
,
Pauline Raaschou
3
,
Gerd Lärfars
4
,
Lars Sandman
2
,
Niklas Juth
5
Affiliations
1
Centre for Applied Ethics, Department of Culture and Society, Linköping University, Linköping, Sweden erik.gustavsson@liu.se.
2
The National Centre for Priorities in Health, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
3
Clinical Pharmacology Unit, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
4
Health and Medical Care Administration, Stockholm, Sweden.
5
Stockholm Centre of Healthcare Ethics, LIME, Karolinska Institute, Stockholm, Sweden.
PMID:
35115409
DOI:
10.1136/medethics-2022-108157
No abstract available
Keywords:
ethics.
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Alzheimer Disease* / drug therapy
Humans